AVTX
AVTX
NASDAQ · Biotechnology

Avalo Therapeutics Inc

$14.19
+1.04 (+7.91%)
As of Feb 8, 2:01 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 35.20M 36.29M 36.66M
Net Income 7.89M 8.09M 8.22M
EPS
Profit Margin 22.4% 22.3% 22.4%
Rev Growth -4.5% +16.8% -1.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 40.58M 45.39M 52.32M
Total Equity 87.21M 96.06M 95.40M
D/E Ratio 0.47 0.47 0.55
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 9.70M 9.50M 9.77M
Free Cash Flow 3.72M 4.67M 3.24M